Navigation Links
Abbott Completes Acquisition of Facet Biotech
Date:4/21/2010

ABBOTT PARK, Ill., April 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) has completed its acquisition of Facet Biotech Corporation, strengthening its pharmaceutical pipeline in immunology and oncology.

The acquisition provides Abbott with a promising biologic intended to treat multiple sclerosis (MS) and compounds that complement its existing diverse oncology program.  The new Abbott compounds include daclizumab – a Phase II investigational biologic intended to treat multiple sclerosis that is expected to move into Phase III development in the second quarter 2010 – and oncology compounds in early- to mid-stage development that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia.

"Facet's depth of biologics experience and sophisticated antibody engineering platforms complement Abbott's current R&D programs in oncology, immunology and other therapeutic areas," said John Leonard, M.D., senior vice president, global pharmaceutical research and development, Abbott.

The final step in the acquisition process was a short-form merger of Amber Acquisition Inc., a wholly-owned subsidiary of Abbott, with and into Facet Biotech Corporation. As a result of the merger, all outstanding shares of Facet common stock not tendered in the cash tender offer (other than those as to which holders properly exercise dissenters' rights) were converted into the right to receive $27 per share in cash, without interest and subject to any required withholding taxes.

About Abbott

Abbott is a global, broad-based health care company devot
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... by Persistence Market Research "Global Market Study on ... to Witness Highest Growth by 2022", the global physiotherapy ... Bn by the end of 2015 and is expected ... 2015 to 2022, to account for US$23.7 Bn by ...
(Date:8/3/2015)...  CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... financial results for the three months ended June 30, ... and upcoming milestones for its clinical development programs. ... productive for CytRx. Enrollment in our ongoing pivotal global ... sarcoma (STS) continues on track to be completed in ...
(Date:8/3/2015)... Aug. 3, 2015  Array BioPharma Inc. (NASDAQ: ... fourth quarter and full year of its fiscal ... Squarer, Chief Executive Officer of Array, noted, "Binimetinib and ... are on track for regulatory submissions in 2016. ... melanoma and BRAF-mutant colorectal cancer further validate the ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... , , , , MUMBAI, India, Dec. ... IN, NSE: SUNPHARMA, BSE: 524715) today announced that based on ... (Pink Sheets: TAROF) annual general meeting, Taro,s minority shareholders sent ... continuing control of Taro. Shareholders voted decisively against the ...
... , DETROIT, Dec. 30 For the twelfth consecutive year, ... Christ, is campaigning to save lives during New Year,s Eve ... New Millennium, Health Alliance Plan (HAP) and the Wayne County ... celebrate the New Year without gunfire. The hope is ...
Cached Medicine Technology:Taro Shareholders to Levitt and Directors: Quit the Board 2Taro Shareholders to Levitt and Directors: Quit the Board 3Rev. Nick Hood, III Asks Southeast Michiganders Not to Use Guns During New Year's Eve Celebrations 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that in ... Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other ...
(Date:8/3/2015)... ... 03, 2015 , ... A recent survey by the ... Hispanics believe people can positively affect their diabetes, few look beyond diet changes ... diet changes was important. Far fewer participants mentioned the need for exercise (30%), ...
(Date:8/3/2015)... ... 2015 , ... Novatus, Inc. today launched the largest and ... as announced the date of its next major release. , Version 6.0 introduces ... as well as enhancements to the customer experience. Users now enjoy a ...
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular North ... NA’s cyclotron sites and research and development facilities. , “We are excited ... a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO of ...
Breaking Medicine News(10 mins):Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... for signed parental consent and health,history forms, Give Kids ... youth population they will see on February 1 - ... agencies and such. PLEASE DO NOT INDICATE TO THE ... COLUMBUS, Ohio, Jan. 24 In conjunction with,the Ohio ...
... at Melbournes Howard Florey Institute have discovered that ... dementia in the fatal genetic disease, Huntington,s disease. ... possibilities for other devastating and difficult to treat ... a key component. , The Floreys Dr ...
... symposium on gastrointestinal cancers , , THURSDAY, Jan. 24 (HealthDay ... a biomarker that could detect colorectal cancer in its ... accurate way than existing blood tests. , The marker, ... early- and late-stage disease, the researchers added. , The ...
... 24 ZYTO Corp. (Pink Sheets:,ZYTC) has announced the ... and Kami Howard as C.F.O., The internal appointments ... according to Dr. Vaughn R. Cook, company founder, president ... and handled the,financial responsibilities., Howard joined ZYTO in ...
... The following is a,statement by Blue Shield of California CEO ... advocate for universal coverage, I,m disappointed that we,did not clear ... Senate must,not make perfection the enemy of the good. This ... be., We have waited too long to make health ...
... Calif., Jan. 23 InterMune, Inc.,(Nasdaq: ITMN ) ... of InterMune, will present at the 2008 Wachovia Healthcare,Conference ... EST., To access a live audio webcast of ... to the investor relations page of InterMune,s,corporate website at ...
Cached Medicine News:Health News:Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio 2Health News:Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio 3Health News:Mental and physical exercise delays dementia in fatal genetic disease 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 3Health News:ZYTO Corp. Appoints New Chief Operations Officer and New Chief Financial Officer 2Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... 10% Povidone Iodine USP, 1% available Iodine, ... prep, Povidone Iodine Gel helps to minimize ... patient, thus reducing the chance of patient ... a one step gel for venipuncture site ...
... Gel is a viscous antimicrobial that contains ... for broad-spectrum germicidal action. As a preoperative ... minimize the pooling of prepping solutions under ... patient burns. Povidone Iodine Topical Gel is ...
... Povidone Iodine Prep Solution is appropriate ... paint, wet soak or spray); disinfecting ... antiseptic treatment of lacerations and abrasions. ... anti-infective agent in hospital and office ...
Medicine Products: